Jim Cramer’s Insights
Discussing on CNBC’s “Mad Money Lightning Round,” Jim Cramer drew attention to Medtronic for its advancements in artificial intelligence, encouraging investors with the promise of a strong yield.
Notably, the FDA’s recent approval of Medtronic’s Evolut FX+ transcatheter aortic valve replacement system for aortic stenosis signifies a significant stride in the healthcare sector.
Turning to Riley Exploration Permian, Inc., Cramer highlighted its undervalued state and appealing yield, urging investors to seize the opportunity.
Meanwhile, WESCO International, Inc. was spotlighted by the “Mad Money” host as a viable investment option.
Interestingly, Cleveland-Cliffs Inc. also made Cramer’s list, who suggested buying the stock below the $20 mark, indicating a perceived potential buying ceiling.
Recent Developments
Recently, Riley Permian unveiled a public stock offering priced at $27.00 per share, providing insights into the company’s financial moves.
On April 1, WESCO International completed a significant business transaction, shedding light on its strategic realignment by selling Wesco Integrated Supply business.
Conversely, Cleveland-Cliffs underwent a downgrade by Wolfe Research, underscoring the nuanced nature of stock recommendations in the volatile market environment.
Price Movements
- Medtronic: Experienced a 1.1% increase to settle at $83.80.
- Riley Exploration Permian: Observed a 1.4% decline, closing at $29.20.
- WESCO International: Registered a 0.1% gain, closing at $172.78.
- Cleveland-Cliffs: Witnessed a 2.3% drop, closing at $21.91.
Read Next: Citizens And 2 Other Stocks Under $3 Insiders Are Buying
Image: Shutterstock
